 AUSTIN, Texas, Aug. 11, 2021 GLOBE NEWSWIRE -- Plus Therapeutics, Inc. Nasdaq: PSTV the Company, a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult to treat cancers, today announced it will present data from one planned clinical trial and one completed preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome 186RNL, for the treatment of leptomeningeal metastases LM. The data will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology SNO, being held virtually August 19-20, 2021. 